317TiP A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
